The landmark breast cancer screening study of women 40-49, published online in Cancer, has proven annual mammography screening of women in their 40s reduces the breast cancer death rate in these women by nearly 30%.
The landmark breast cancer screening study of women 40-49, published online in Cancer, has proven annual mammography screening of women in their 40s reduces the breast cancer death rate in these women by nearly 30%. The results of the largest study ever conducted on women in this age group confirm the use of the age of 50 as a threshold for breast cancer screening is scientifically unfounded. Women should begin getting annual mammograms at age 40.
"This study, which looked at the performance of screening mammography as it is actually used, rather than relying on mathematical modeling, shows without a doubt that mammography decreases deaths from breast cancer in women aged 40-49 by nearly one third. There is no excuse not to recommend that average risk women begin annual screening mammography at age 40," said Dr. Carol H. Lee, chair of the American College of Radiology Breast Imaging Commission.
In November of 2009, the United States Preventive Services Task Force (USPSTF) ignored published data showing a similar death rate reduction to this landmark trial, and withdrew support for screening women 40-49. This real world study is far more robust, based on real world numbers, and proves the benefit is nearly twice that of the USPSTF estimate of 15%.
"This study shows annual mammograms for women 40 and older result in a tremendously significant reduction in the breast cancer death rate for women 40-49. The age of 50 is an artificial threshold that has no basis in scientific fact. The debate is now over. Women should no longer be confused about the importance of annual breast cancer screening. Mammography saves lives. If you are a woman age 40 or over, one of them could be yours," said Dr. Phil Evans, president of the Society of Breast Imaging.
The Swedish trial followed more than 600,000 women for 16 years. The number of breast cancer deaths among the women in the study who did not receive mammograms was twice as high as those who underwent screening. Breast cancer is the most common cancer in women worldwide. It kills around 465,000 people globally each year. Mammography can catch cancer early, when it is most treatable. While not a perfect test, at present, there is no other screening tool to replace it.
"It is now time to stop confusing women with conflicting information. Mammography is a lifesaver for women in their 40s. What providers need to do now is uniformly confirm for women they need to start getting annual mammograms beginning at age 40 and work to build on the ability of mammography to detect cancer early, when it is most treatable. Mammography saves a significant number of lives in all women 40 and over. Let's all move forward from there," said Dr. Gail Lebovic, breast surgeon and president of the American Society of Breast Disease.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.